Simvoget

Min Order:

 

Port:

TBA

 

Production Capacity:

 

Payment Terms:

Nil

 

Company Name:

Getz Pharma Inc.

 

Price:

 

Simvoget®

Therapeutic Segment: Anti-Lipidemic

Generic Name: Simvastatin

Indication:

As adjunct to diet when response to nondrug therapy is inadequate: primary hypercholesterolemia (heterozygous familial and no familial) and mixed dyslipidemia (Types lla and llb); hypertriglyceridemia (Type IV) or primary dysbetalipoproteinemia (Type III); adjunct to or when other lipid-lowering treatments for homozygous familial hypercholesterolemia (HoFH) are not available, to reduce total-C and LDL-C. In patients with coronary heart disease (CHD), diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease to reduce: risk of total mortality by reducing CHD death, risk of non-fatal MI and stroke, risk for undergoing myocardial revascularization procedures. Adjunct to diet to reduce total-C, LDL-C, and apo B in patients 10–17 years of age (≥1yr post-menarche) with heterozygous familial hypercholesterolemia if  LDL-C remains ≥190mg/dL, or if LDL-C remains ≥160mg/dL with either family history of premature cardiovascular disease (CVD) or if patient has at least 2 other CVD risk factors.

Available as:

Tablets

• 10MG
• 20MG
• 40MG